Vallon Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.36 Insider Own53.09% Shs Outstand6.81M Perf Week-6.95%
Market Cap3.80M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float3.20M Perf Month-65.82%
Income-9.30M PEG- EPS next Q-0.23 Inst Own6.00% Short Float2.76% Perf Quarter-93.38%
Sales- P/S- EPS this Y-100.90% Inst Trans-14.32% Short Ratio0.02 Perf Half Y-92.74%
Book/sh0.49 P/B1.08 EPS next Y- ROA-103.10% Target Price- Perf Year-87.85%
Cash/sh0.71 P/C0.75 EPS next 5Y- ROE-134.00% 52W Range0.34 - 10.36 Perf YTD-91.14%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-94.89% Beta-
Dividend %- Quick Ratio2.30 Sales past 5Y- Gross Margin- 52W Low55.82% ATR0.19
Employees3 Current Ratio2.30 Sales Q/Q- Oper. Margin- RSI (14)27.81 Volatility22.91% 20.18%
OptionableNo Debt/Eq0.03 EPS Q/Q16.30% Profit Margin- Rel Volume0.06 Prev Close0.52
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume3.65M Price0.53
Recom2.00 SMA20-45.35% SMA50-71.41% SMA200-89.25% Volume222,694 Change2.75%
May-13-22 08:30AM  
May-12-22 08:30AM  
May-11-22 08:35AM  
May-09-22 04:05PM  
Apr-22-22 08:00AM  
Mar-23-22 08:00AM  
Mar-21-22 11:02AM  
Mar-04-22 02:34PM  
Feb-28-22 04:05PM  
Feb-14-22 04:15PM  
Jan-25-22 09:54AM  
Jan-20-22 08:35AM  
Jan-18-22 08:05AM  
Jan-12-22 10:35AM  
Jan-04-22 08:05AM  
Dec-23-21 08:05AM  
Dec-12-21 04:27AM  
Nov-12-21 08:05AM  
Nov-11-21 08:05AM  
Nov-10-21 08:35AM  
Nov-04-21 02:30PM  
Nov-01-21 08:35AM  
Oct-26-21 03:23PM  
Oct-12-21 08:35AM  
Sep-14-21 08:05AM  
Aug-11-21 08:05AM  
Aug-10-21 08:05AM  
Jul-13-21 08:05AM  
May-30-21 04:48AM  
May-19-21 08:15AM  
May-13-21 09:15AM  
May-11-21 09:05AM  
May-07-21 08:05AM  
Apr-26-21 09:05AM  
Apr-13-21 08:05AM  
Mar-29-21 08:05AM  
Mar-03-21 08:35AM  
Feb-23-21 09:05AM  
Feb-12-21 03:30PM  
Feb-09-21 10:24PM  
Vallon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel abuse-deterrent medications for central nervous system disorders. Its lead investigational product candidate is ADAIR, an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. The company is also developing ADMIR, an abuse deterrent formulation of methylphenidate for the treatment of ADHD. Vallon Pharmaceuticals, Inc. was incorporated in 2018 and is based in Philadelphia, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kelly Leanne M.Chief Financial OfficerJun 04Buy4.081,5086,1536,250Jun 04 04:06 PM
Kelly Leanne M.Chief Financial OfficerJun 03Buy4.051,0854,3944,742Jun 04 04:06 PM
Kelly Leanne M.Chief Financial OfficerJun 02Buy4.003,65714,6283,657Jun 04 04:06 PM